{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigfl7mgnl3n637nypjvhgrzwofxqsha2ixfx4pt3ynk64dtmyokae",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mpmfddkpl3s2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihqlvsopfqoqons3abeqobb2zfxw6qw3x5javvwavg7dei3nz6ata"
    },
    "mimeType": "image/jpeg",
    "size": 2415218
  },
  "path": "/news/2026-07-results-phase-ii-trial-therapy.html",
  "publishedAt": "2026-07-01T16:00:09.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Results of the ongoing eNRGy trial, a single-arm, multicenter, global Phase II clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy—including a near doubling of progression-free survival compared with expectations with standard of care—in previously treated patients with advanced NRG1-positive cholangiocarcinoma.",
  "title": "Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer"
}